Cullinan's lung cancer trial met its main goal; results are set for presentation in September
Cullinan Therapeutics (CGEM) announced that its Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC met its primary endpoint of progression-free survival. The positive results have been selected for presentation at the Presidential Symposium 2 of the IASLC 2026 World Conference on Lung Cancer in September 2026. This trial evaluated zipalertinib in combination with chemotherapy against chemotherapy alone for patients with this specific type of non-small cell lung cancer.
UBS raises Cullinan Oncology stock price target to $27 on trial data
UBS has increased its price target for Cullinan Oncology Inc. (NASDAQ:CGEM) to $27 from $24, while maintaining a Buy rating. This adjustment follows positive Phase 3 trial results for zipalertinib in treating first-line EGFR exon 20 insertion non-small cell lung cancer. The firm also raised the probability of success for zipalertinib in this indication to 85% from 40%, projecting significant peak sales potential.
UBS raises Cullinan Oncology stock price target to $27 on trial data
UBS has increased its price target for Cullinan Oncology (NASDAQ:CGEM) to $27 from $24, maintaining a Buy rating, following positive Phase 3 trial results for zipalertinib. The drug, developed with Taiho, showed significant progression-free survival benefit in first-line EGFR exon 20 insertion non-small cell lung cancer, leading UBS to raise its probability of success for zipalertinib in this indication to 85%. Despite the stock's recent surge and proximity to its 52-week high, InvestingPro suggests it may be overvalued.
Cullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & History
This article provides comprehensive information on Cullinan Therapeutics, Inc. (CGEM), including its current stock price, financial metrics, and a history of recent news and press releases. The company, a biopharmaceutical firm, focuses on developing cancer therapies and has announced several key clinical milestones and FDA designations for its drug candidates.
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy met its primary endpoint of progression-free survival in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The study showed a statistically significant and clinically meaningful improvement in PFS with manageable safety. The companies plan to seek U.S. regulatory approval for this combination regimen based on these positive interim results.
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for zipalertinib combined with chemotherapy in first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The Independent Data Monitoring Committee recommended unblinding the study, and the companies plan to seek U.S. regulatory approval. Full results will be presented at an upcoming international medical conference.
Cullinan Oncology stock hits 52-week high at 19.43 USD
Cullinan Oncology (CGEM) stock has reached a 52-week high of $19.43, reflecting a significant increase of approximately 158% over the past year. The biotech company, now valued at $1.24 billion, is trading above its Fair Value according to InvestingPro analysis. Recent developments include positive FDA feedback for CLN-049, upcoming Phase 2 studies, and analyst confidence in the company's trial data for autoimmune disease drug candidates.
Cullinan Oncology stock hits 52-week high at 19.43 USD By Investing.com
Cullinan Oncology (CGEM) stock has reached a new 52-week high of $19.43, reflecting a substantial increase of approximately 158% over the past year. The company's market capitalization now stands at $1.24 billion, driven by strong investor confidence and recent positive developments. These include favorable FDA feedback for its CLN-049 drug candidate and ongoing clinical trials for autoimmune disease treatments, leading analysts to reiterate positive ratings.
(CGEM) Movement as an Input in Quant Signal Sets
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models to generate trading strategies. It highlights a strong near-term sentiment possibly leading to a long-term positive bias, with support being tested. The analysis provides specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies, emphasizing the exceptional risk-reward setup.
(CGEM) Movement as an Input in Quant Signal Sets
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) using AI models to generate trading strategies. It highlights a strong near-term sentiment with potential for a 50.2:1 risk-reward setup, targeting a 14.3% gain. The analysis provides specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies across multiple timeframes.
Renaissance Technologies LLC Sells 307,595 Shares of Cullinan Therapeutics, Inc. $CGEM
Renaissance Technologies LLC has reduced its stake in Cullinan Therapeutics (NASDAQ:CGEM) by 48.7% during the first quarter, selling 307,595 shares and retaining 324,111 shares valued at $4.6 million. Despite this sale, institutional investors collectively hold 86.31% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average target price of $32.14. Cullinan Therapeutics, a biopharmaceutical company focused on oncology therapies, recently reported a quarterly loss of $0.81 per share, slightly below consensus estimates.
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Cullinan Therapeutics announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its immunology and oncology pipeline. The company reported promising clinical data for CLN-978 and velinotamig in autoimmune diseases, with Phase 2 studies anticipated to begin in early 2027. Additionally, a potentially registrational Phase 2 study for CLN-049 in relapsed/refractory AML is set to start in Q3 2026, and the company maintains a strong cash position of $356 million, extending its runway into 2029.
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history
This article provides a detailed overview of Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company focused on autoimmune diseases and cancer. It includes current stock price, historical data, financial metrics, analyst ratings, and a company profile highlighting its drug development pipeline. The company's stock has seen significant returns year-to-date and over the past year, and analysts have maintained a "Buy" rating with an increased price target.
Cullinan to begin potentially registrational acute myeloid leukemia study in Q3
Cullinan Therapeutics reported a Q2 2026 net loss of $53.7 million but maintained a strong cash position of $356 million, providing a runway into 2029. The company announced several upcoming clinical milestones for its immunology and oncology pipeline, including the initiation of a potentially registrational Phase 2 study for CLN-049 in relapsed/refractory AML in Q3 2026. Additionally, the FDA accepted the NDA for zipalertinib in EGFR ex20ins NSCLC with a PDUFA date of February 27, 2027.
Cullinan Oncology earnings up next: Can pipeline justify cash burn?
Cullinan Therapeutics Inc. is set to report second-quarter earnings, with analysts expecting a wider loss per share. The pre-revenue biotech, with a $1.08 billion market cap, is advancing two late-stage oncology programs, CLN-049 and zipalertinib, which have garnered bullish Wall Street sentiment and significant upside projections. Investors will focus on operating expenses, cash burn rates, and management's commentary on funding requirements as the company progresses its capital-intensive programs toward potential commercialization.
Liquidity Mapping Around (CGEM) Price Events
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies key support and resistance levels, offering three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The analysis emphasizes a significant 49.4:1 risk-reward setup for a potential 14.2% gain.
For AML patients with limited options, Cullinan plans a new study
Cullinan Therapeutics received positive feedback from the FDA for its FLT3xCD3 T cell engager CLN-049 in acute myeloid leukemia (AML), paving the way for a potentially registrational Phase 2 study in Q3 2026. The study will focus on relapsed/refractory AML, an area with limited treatment options, and will include a dose-optimization phase followed by a single-arm cohort. CLN-049 has already demonstrated promising clinical activity and a favorable safety profile, holding Orphan Drug and Fast Track designations.
Why is Cullinan Therapeutics stock climbing today?
Cullinan Therapeutics (CGEM) stock rose in pre-open trading after receiving positive FDA feedback for CLN-049, a drug for relapsed/refractory acute myeloid leukemia. The company plans to initiate a potentially registrational Phase 2 study in Q3 2026, which investors view as an accelerated path to regulatory approval. This news, along with existing Fast Track and Orphan Drug designations, provided a strong catalyst for CGEM's stock, despite a broader market downturn for biotech names.
Why (CGEM) Price Action Is Critical for Tactical Trading
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) for tactical trading, highlighting a mid-channel oscillation pattern and a significant 51.8:1 risk-reward setup. It outlines various trading strategies including position trading, momentum breakout, and risk hedging, based on AI-generated signals and multi-timeframe analysis. The report suggests potential choppy conditions due to divergent sentiment across different time horizons.
Cullinan CSO sells shares, exercises options | CGEM Insider Trading
Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, executed an exercise-and-sell transaction. She sold 8,000 shares of common stock at a weighted average price of $17.82 per share under a pre-arranged Rule 10b5-1 trading plan and simultaneously exercised stock options for 4,000 shares at $4.30 per share. Following these transactions, Michaelson directly owns 162,844 shares of common stock and holds 112,987 exercisable stock options.
CGEM (NASDAQ) insider resale notice: 8,000 shares proposed, prior 10b5-1 sales noted
A Form 144 filing by CGEM (Cullinan Therapeutics, Inc.) indicates a proposed resale of 8,000 shares of common stock from insider-related sources. This includes 4,000 shares from exercised stock options (dated 07/06/2026) and 4,000 shares from Restricted Stock Units (dated 02/22/2024). The filing also notes prior 10b5-1 sales of 8,000 shares on 05/05/2026, generating proceeds of $116,976.02, and names Morgan Stanley Smith Barney LLC as the broker for the proposed sales.
Why (CGEM) Price Action Is Critical for Tactical Trading
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) for tactical trading, identifying a weak near-term sentiment but strong mid- and long-term outlook. It highlights a significant 53.2:1 risk-reward short setup and provides specific AI-generated trading strategies including position, momentum breakout, and risk hedging, with defined entry, target, and stop-loss levels across various time horizons.
Cullinan Therapeutics (CGEM) CFO adds 1,541 shares through ESPP purchase
Cullinan Therapeutics' CFO, Mary Kay Fenton, acquired 1,541 shares of company common stock through the 2021 Employee Stock Purchase Plan. The shares were purchased at $8.60 each, based on 85% of the closing price on January 2, 2026, for the period of January 1 to June 30, 2026. Following this transaction, Fenton directly holds 127,921 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics (CGEM) CLO adds 2,470 ESPP shares at $8.60
Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L. Sumer, acquired 2,470 shares of common stock at $8.60 per share through the company's 2021 Employee Stock Purchase Plan. This routine transaction, which occurred between January 1 and June 30, 2026, increases her direct holdings to 130,559 shares. The shares were purchased at 85% of the closing price on January 2, 2026, and the transaction is exempt under Rule 16b-3(c).
EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innovative Medicine
The EGFR-NSCLC market is projected to grow significantly, from USD 7.0 billion in 2025 to USD 16.0 billion by 2036, driven by targeted therapies and advancements in treatment. Key companies like AstraZeneca, J&J, and others are actively developing and launching therapies such as amivantamab and osimertinib, which are expected to generate the highest revenues. The report highlights emerging therapies, increasing biomarker testing, and a rich pipeline as market drivers, while cost-effectiveness and small patient populations pose potential barriers.
Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com
Cullinan Oncology (CGEM) stock recently hit a 52-week high of $17.97, reflecting a significant 127.68% increase over the past year. Despite an InvestingPro analysis suggesting potential overvaluation, the company, with a $1.1 billion market capitalization, continues to show strong growth. Recent developments include positive clinical trial data, an Orphan Drug Designation from the FDA, and maintained "Buy" and "Outperform" ratings from analysts, highlighting confidence in its R&D.
Cullinan Therapeutics (CGEM) Is Up 31.0% After Autoimmune T Cell Engager Data – Has The Bull Case Changed?
Cullinan Therapeutics (CGEM) stock surged 31.0% after reporting positive Phase 1 data for its T cell engagers, CLN-978 and velinotamig, in autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. This data indicates strong clinical responses and favorable safety, positioning the company to expand beyond oncology into treating chronic autoimmune conditions. While this strengthens Cullinan's investment narrative and upcoming readouts, the company remains loss-making and reliant on new capital, with potential dilution risks.
Understanding Momentum Shifts in (CGEM)
This article provides an in-depth analysis of Cullinan Oncology Inc. (CGEM) using AI models to identify momentum shifts and suggest trading strategies. It highlights strong sentiment across all time horizons supporting an overweight bias and points out that resistance is being tested. The analysis includes distinct strategies for different risk profiles, offering various entry and exit points, alongside support and resistance levels.
Cullinan Oncology stock hits 52-week high at $17.97
Cullinan Oncology LLC's stock reached a 52-week high of $17.97, and is currently trading just 1% below this peak. The company has recently reported positive clinical trial data, received Orphan Drug Designation for CLN-049, and held its Annual Meeting of Stockholders. Analysts from William Blair and Stifel have reiterated 'Outperform' and 'Buy' ratings, respectively, based on the company's research and development efforts.
Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com
Cullinan Oncology's stock reached a 52-week high of $17.97, reflecting a 127.68% increase over the past year and strong investor confidence despite being potentially overvalued according to InvestingPro. The biotech firm, with a $1.1 billion market capitalization, continues to advance its drug candidates for autoimmune diseases and acute myeloid leukemia, supported by positive analyst ratings from William Blair and Stifel.
Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com
Cullinan Oncology (CGEM) stock has reached a new 52-week high of $17.97, reflecting a 127.68% increase over the past year. Despite an InvestingPro analysis suggesting the stock may be overvalued, the company, with a market capitalization of $1.1 billion, continues to demonstrate strong growth and investor confidence, supported by positive clinical trial data and analyst ratings.
Cullinan Therapeutics (CGEM) Citi’s 2026 Virtual Oncology Leadership Summit Summary
Cullinan Therapeutics discussed its pipeline strategy at Citi’s 2026 Virtual Oncology Leadership Summit, highlighting T-cell engagers CLN-978 for autoimmune diseases and CLN-049 for AML as key catalysts for the year. The company aims for transformative potential with first-in-class or best-in-class molecules. CLN-049 showed promising monotherapy efficacy in AML, while zipalertinib for NSCLC is nearing NDA completion with a significant market opportunity.
Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant
Cullinan Therapeutics director Andrew R. Allen was granted stock options for 21,781 shares of common stock with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or the company's next annual meeting, provided his continued board service. This grant is classified as a compensatory award and not an open-market transaction.
Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike
Cullinan Therapeutics director Mary Thistle was granted 25,319 stock options with an exercise price of $13.55 per share. The options will vest in full by June 16, 2027, or the company's next annual meeting, provided she continues her service as a director. This grant is part of her equity-based compensation and is tied to her ongoing role on the board.
Cullinan Therapeutics (CGEM) grants director 25,319 stock options
Cullinan Therapeutics (CGEM) director Anthony Rosenberg was granted 25,319 stock options with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or at the company's next annual meeting, provided he continues his board service. The Form 4 filing reported no open-market buying or selling by Rosenberg, showing only this compensation grant.
Cullinan Therapeutics (CGEM) grants director Mittie Doyle 21,781 stock options
Cullinan Therapeutics director Mittie Doyle was granted 21,781 stock options at an exercise price of $13.55 per share. The options will vest in full on the earlier of June 16, 2027, or the company's next annual meeting, provided she continues her service as a director. This transaction is classified as a compensation award rather than an open-market trade.
Cullinan Therapeutics shareholders elect directors and approve proposals at annual meeting
Cullinan Therapeutics (NASDAQ: CGEM) shareholders elected two Class III directors for three-year terms, ratified KPMG LLP as the independent registered public accounting firm, and approved an advisory vote on executive compensation at their annual meeting. The biotech company has seen a 56% stock increase over the past year, with analysts maintaining a "strong buy" consensus. Recent news also highlights clinical trial data for autoimmune drug candidates and Orphan Drug Designation for CLN-049.
Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM)
Cullinan Therapeutics director David D. Meek was granted 25,319 stock options with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or the date of the company's next annual meeting, contingent on his continued service as a director. This grant is part of his compensation and not an open-market purchase.
Cullinan Therapeutics (NASDAQ: CGEM) shareholders back directors, KPMG and pay
Cullinan Therapeutics (NASDAQ: CGEM) shareholders held their Annual Meeting on June 16, 2026, where they elected two Class III directors, Nadim Ahmed and Stephen Webster, to three-year terms. They also ratified KPMG LLP as the independent registered accounting firm for 2026 and approved the advisory vote on executive compensation for named executive officers. All three proposals received the required support from stockholders.
Avoiding Lag: Real-Time Signals in (CGEM) Movement
Cullinan Oncology Inc. (NASDAQ: CGEM) is showing weak near and mid-term sentiment but a strong long-term outlook, according to AI models. The article details three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels. It highlights an exceptional 60.3:1 risk-reward setup targeting a 19.0% gain versus 0.3% risk.
[8-K] Cullinan Therapeutics, Inc. Reports Material Event
Cullinan Therapeutics (NASDAQ: CGEM) has reported early-stage clinical data for its T cell engager programs CLN-978 and velinotamig, targeting autoimmune diseases. CLN-978 showed robust efficacy, including remission in a rheumatoid arthritis patient, and velinotamig demonstrated favorable safety and complete renal responses in systemic lupus erythematosus (SLE) patients. The company plans further data releases for both programs and new trial initiations in early 2027, indicating continued development in this therapeutic area.
Cullinan Therapeutics reports promising autoimmune trial data
Cullinan Therapeutics announced promising initial clinical data for its dual-targeting T-cell engager, CLN-978, showing its potential in autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company reported clinical remissions and B-cell depletion in difficult-to-treat patients, with plans to expand its Phase 2a trial for lupus nephritis. This marks an expansion into the autoimmune space for the oncology-focused biotech.
Cullinan reports clinical data for autoimmune drug candidates
Cullinan Therapeutics Inc. reported promising clinical data for two T cell engager drug candidates, CLN-978 and velinotamig, targeting autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis. Despite a recent stock decline, the company saw positive patient responses and plans further data releases and trial expansions. Analysts maintain positive ratings, with some raising price targets, highlighting the potential of Cullinan’s pipeline.
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
Cullinan Therapeutics announced new clinical data from its T cell engager programs targeting CD19 (CLN-978) and BCMA (velinotamig) for autoimmune diseases. CLN-978 showed potential for immune reset and clinical remissions in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), with additional multi-dose data expected in Q3 and Q4 2026. Velinotamig demonstrated promising clinical activity, including complete renal responses in lupus nephritis, and is slated for a Phase 1/2a trial in autoimmune cytopenias in Q1 2027.
Cullinan Therapeutics (CGEM) posts early CLN-978 SLE and RA remission data
Cullinan Therapeutics reported initial Phase 1 data for CLN-978, a T cell engager, in treatment-refractory systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), showing meaningful clinical and biologic signals. In SLE, 71% of patients achieved a significant reduction in disease activity, with 5 reaching remission, and in RA, 71% showed improved disease activity. The drug demonstrated deep, dose-dependent B cell depletion without affecting protective vaccine titers and exhibited a generally well-tolerated safety profile at target doses up to 30 µg, with mostly Grade 1 cytokine release syndrome
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Cullinan Therapeutics presented initial Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, at the EULAR 2026 Congress, demonstrating clinical benefit and remission in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The data showed deep, dose-dependent B cell depletion and a favorable safety profile. The company plans to share additional data, including from multi-dose regimens and initial clinical data for velinotamig, at its upcoming Immunology Day.
Discipline and Rules-Based Execution in CGEM Response
Cullinan Oncology Inc. (NASDAQ: CGEM) is showing strong near-term sentiment with a long-term positive bias, according to AI models. The analysis highlights a 63.5:1 risk-reward setup targeting a 16.9% gain with minimal risk. Three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—are provided, along with multi-timeframe signal analysis, to assist with various risk profiles and holding periods.
Discipline and Rules-Based Execution in CGEM Response
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), identifying a near-term strong sentiment potentially shifting to neutral mid-term and positive long-term. It highlights an exceptional 63.5:1 risk-reward setup targeting a 16.9% gain with minimal risk and provides three AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging. The analysis is supported by multi-timeframe signals indicating support and resistance levels.
CGEM - Cullinan Therapeutics Inc Stock Price and Quote
Cullinan Therapeutics Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing oncology and immuno-oncology therapies. The article provides detailed financial data, analyst ratings, and a comprehensive list of recent company news and insider transactions, indicating active development in its drug pipeline and significant insider buying and selling activities.
New lupus and arthritis drug data to be unveiled at Cullinan Immunology Day
Cullinan Therapeutics will host an Immunology Day on June 10, 2026, to showcase new and updated clinical data for its lead immunology programs, CLN-978 and velinotamig. The event will detail results from over 30 patients in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies for CLN-978, including initial multi-dose cohort data for RA, and initial multi-dose data for velinotamig in treatment-refractory autoimmune diseases. This aims to validate the potential of their T cell engagers in autoimmune diseases, with management and key opinion leaders presenting.
